Floatz logo

Zactima

Von Hippel Lindau

National Cancer Institute (NCI)Phase 2Dormant
B
56/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
41/ 100
Competitive Position
95/ 100

Competitive context

10 Active assets in the Von Hippel Lindau cohort.

Asset / SponsorPhaseRating
Belzutifan
Merck Sharp & Dohme LLC
Phase 3BB
Palbociclib
Merck Sharp & Dohme LLC
Phase 3B
LENVATINIB
Merck Sharp & Dohme LLC
Phase 3B
Bms-907351
Merck Sharp & Dohme LLC
Phase 3B
Nivolumab
Merck Sharp & Dohme LLC
Phase 3B

View all 16 →

Same molecule, other indications

Zactima is also rated in:

metastatic neoplasmDormant
B
Indicative ·
63 / 100
View asset →
gliosarcomaDormant
B
Indicative ·
63 / 100
View asset →
non-small cell lung carcinomaDormant
B
Indicative ·
61 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →